Menora Mivtachim Holdings LTD. Purchases New Holdings in Novo Nordisk A/S (NYSE:NVO)

Menora Mivtachim Holdings LTD. purchased a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 842,968 shares of the company's stock, valued at approximately $72,512,000.

Other large investors also recently made changes to their positions in the company. Savvy Advisors Inc. boosted its position in Novo Nordisk A/S by 91.1% during the fourth quarter. Savvy Advisors Inc. now owns 7,123 shares of the company's stock worth $613,000 after purchasing an additional 3,395 shares during the period. Synovus Financial Corp lifted its stake in shares of Novo Nordisk A/S by 26.3% in the fourth quarter. Synovus Financial Corp now owns 69,094 shares of the company's stock worth $5,944,000 after buying an additional 14,397 shares during the last quarter. Stamos Capital Partners L.P. grew its stake in Novo Nordisk A/S by 730.8% in the 4th quarter. Stamos Capital Partners L.P. now owns 17,280 shares of the company's stock valued at $1,486,000 after buying an additional 15,200 shares during the last quarter. Advisors Capital Management LLC raised its holdings in Novo Nordisk A/S by 7.9% in the 4th quarter. Advisors Capital Management LLC now owns 8,912 shares of the company's stock worth $767,000 after acquiring an additional 649 shares during the period. Finally, Sagespring Wealth Partners LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth $1,664,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $4.89 on Thursday, reaching $57.99. The company's stock had a trading volume of 32,192,935 shares, compared to its average volume of 5,952,677. Novo Nordisk A/S has a 52 week low of $57.36 and a 52 week high of $148.15. The firm has a market cap of $260.23 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The business has a 50-day moving average price of $76.55 and a 200 day moving average price of $92.55. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 49.54%.

Wall Street Analyst Weigh In

NVO has been the subject of several research analyst reports. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday. They issued an "underperform" rating on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.